Baricitinib in Relapsing Giant Cell Arteritis
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Matthew J Koster
- Study ID
- NCT03026504
- Phase
- PHASE2
- Status
- Completed
Conditions
- Arteritis, Giant Cell
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Baricitinib — DRUG4 milligrams oral Baricitinib daily for 52 weeks
Study Details
This study will evaluate the safety and effectiveness of baricitinib in the treatment of giant cell arteritis. All participants will be taking prednisone at the start of the study. The prednisone will be reduced according to a standardized tapering schedule while participants continue to take one tablet of baricitinib daily for 52 weeks.
Key Dates
- Start date
- Mar 9, 2017
- Status verified
- Apr 2022
- Primary completion
- Apr 12, 2021
- Completion
- Apr 12, 2021
Study Design
- Enrollment
- 15 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Baricitinib Therapy4 milligrams oral Baricitinib daily for 52 weeks
Primary Outcome Measure
Adverse Events [ Time Frame: 52 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | - |
Find similar trials in Rochester, MN
By research site